Can suzetrigine (Journavx) be used continuously for longer than two weeks?

Can Suzetrigine Be Used for Longer Than 2 Weeks Continuously?

Yes, suzetrigine (Journavx) can be used continuously for up to 14 days based on FDA-approved labeling, but clinical trial data does not extend beyond this duration for safety and efficacy. 1

FDA-Approved Duration

The FDA label explicitly states that in the open-label Phase 3 study (Trial 3), patients received suzetrigine for up to 14 days or until their pain resolved, whichever came first 1. The mean duration of treatment was 9.6 days in this study 1. This establishes 14 days as the maximum studied and approved duration for continuous use.

Clinical Trial Evidence

• Trial 3 specifically evaluated extended use: 256 patients received suzetrigine continuously, with the majority (87%) treated for post-surgical pain 1
• Only 2% discontinued due to adverse events (arrhythmia, nausea, somnolence, rash) and 1.6% due to lack of efficacy 1
• The safety profile remained consistent with shorter-duration trials (48-hour studies) 1

Key Safety Considerations Beyond 2 Weeks

There is no clinical data supporting use beyond 14 days. The following concerns emerge from the available evidence:

Renal Function Monitoring

• 2.5% of patients experienced eGFR decreases of ≥25% but <50% during treatment 1
• These decreases appeared to resolve by final safety follow-up, but no long-term data exists 1
• Avoid use entirely if eGFR <15 mL/min 1

Hepatic Considerations

• Patients with moderate hepatic impairment had greater suzetrigine and M6-SUZ exposure, increasing adverse reaction risk 1
• Avoid use in severe hepatic impairment (Child-Pugh Class C) 1

Drug Interactions

• Suzetrigine is a CYP3A inducer and substrate 1
• Contraindicated with strong CYP3A inhibitors 1
• Requires dose reduction with moderate CYP3A inhibitors 1

Clinical Context: Acute vs. Chronic Pain

Suzetrigine is FDA-approved exclusively for moderate-to-severe acute pain 2, 3. The distinction is critical:

• All pivotal trials evaluated acute postoperative or traumatic pain 2
• No chronic pain data exists in approved labeling 3, 4
• Ongoing research is evaluating chronic conditions (diabetic neuropathy, radiculopathy), but results are not yet available 5

Practical Algorithm for Duration Decisions

For acute pain management:

1. Days 1-14: Continue suzetrigine if pain persists and no adverse effects occur
2. Day 14: Reassess pain etiology
   • If acute pain resolving → discontinue
   • If pain persisting → do not extend beyond 14 days; transition to alternative analgesic strategy
3. Monitor throughout: Check for eGFR changes, drug interactions, and adverse effects

If pain extends beyond 2 weeks, this suggests either:

• Transition to subacute/chronic pain (requires different therapeutic approach)
• Inadequate treatment of underlying condition
• Need for multimodal analgesia or specialist consultation

Critical Caveat

One case report describes a 16-year-old receiving a 14-day course with rapid pain intensification within 24 hours of stopping 6. This suggests potential for rebound pain, though this is a single pediatric case (suzetrigine is not FDA-approved for pediatric use) 1.

Bottom Line

Limit suzetrigine to a maximum of 14 consecutive days. Beyond this duration, no safety or efficacy data exists, and the indication shifts from acute to chronic pain—a condition for which suzetrigine lacks approval and evidence. If pain persists beyond 2 weeks, reevaluate the diagnosis and consider alternative pain management strategies rather than extending suzetrigine treatment.